U
16.36
1.18 (7.77%)
| Previous Close | 15.18 |
| Open | 15.62 |
| Volume | 1,348,728 |
| Avg. Volume (3M) | 3,341,964 |
| Market Cap | 1,022,981,184 |
| Price / Earnings (Forward) | 27.93 |
| Price / Sales | 196.41 |
| Price / Book | 2.83 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Operating Margin (TTM) | -2,815.25% |
| Diluted EPS (TTM) | -4.38 |
| Quarterly Revenue Growth (YOY) | -81.50% |
| Total Debt/Equity (MRQ) | 1,522.46% |
| Current Ratio (MRQ) | 11.99 |
| Operating Cash Flow (TTM) | -166.25 M |
| Levered Free Cash Flow (TTM) | -122.89 M |
| Return on Assets (TTM) | -15.64% |
| Return on Equity (TTM) | -241.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | uniQure N.V. | Bearish | Bullish |
AIStockmoo Score
-0.1
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.09% |
| % Held by Institutions | 91.95% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (HC Wainwright & Co., 327.87%) | Buy |
| Median | 33.00 (101.71%) | |
| Low | 9.00 (Cantor Fitzgerald, -44.99%) | Hold |
| 9.00 (Goldman Sachs, -44.99%) | Hold | |
| Average | 35.00 (113.94%) | |
| Total | 5 Buy, 3 Hold | |
| Avg. Price @ Call | 16.54 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 11 Mar 2026 | 35.00 (113.94%) | Buy | 17.56 |
| 03 Mar 2026 | 12.00 (-26.65%) | Hold | 9.03 | |
| HC Wainwright & Co. | 10 Mar 2026 | 70.00 (327.87%) | Buy | 18.26 |
| 10 Feb 2026 | 70.00 (327.87%) | Buy | 24.71 | |
| Chardan Capital | 09 Mar 2026 | 31.00 (89.49%) | Buy | 17.99 |
| 03 Mar 2026 | 16.00 (-2.20%) | Buy | 9.03 | |
| RBC Capital | 09 Mar 2026 | 35.00 (113.94%) | Buy | 17.99 |
| Wells Fargo | 09 Mar 2026 | 60.00 (266.75%) | Buy | 17.99 |
| 03 Mar 2026 | 15.00 (-8.31%) | Hold | 9.03 | |
| Goldman Sachs | 03 Mar 2026 | 9.00 (-44.99%) | Hold | 9.03 |
| Cantor Fitzgerald | 02 Mar 2026 | 9.00 (-44.99%) | Hold | 10.50 |
| Barclays | 28 Jan 2026 | 31.00 (89.49%) | Hold | 23.02 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Mar 2026 | CNBC | FDA reversals leave investors worrying about the fates of other experimental drugs |
| 06 Mar 2026 | CNBC | FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease |
| 09 Jan 2026 | Announcement | uniQure Announces Type A Meeting Scheduled with FDA |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |